End-of-day quote
Korea S.E.
18:00:00 2024-06-30 EDT
|
5-day change
|
1st Jan Change
|
14,100
KRW
|
+0.50%
|
|
-1.05%
|
-4.08%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
69,223
|
50,663
|
69,223
|
85,999
|
41,515
|
87,278
|
Enterprise Value (EV)
1 |
67,781
|
54,775
|
76,304
|
88,281
|
48,469
|
93,613
|
P/E ratio
|
-9.65
x
|
-7.62
x
|
-28.1
x
|
-47.5
x
|
-6.69
x
|
-9.22
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.8
x
|
8.07
x
|
8.13
x
|
8.38
x
|
4.79
x
|
15.6
x
|
EV / Revenue
|
16.5
x
|
8.73
x
|
8.96
x
|
8.6
x
|
5.6
x
|
16.7
x
|
EV / EBITDA
|
-17.8
x
|
-24.7
x
|
58.1
x
|
37.6
x
|
-35.1
x
|
-24.3
x
|
EV / FCF
|
-7.24
x
|
-12.3
x
|
84.6
x
|
-40.3
x
|
-13.4
x
|
-48.5
x
|
FCF Yield
|
-13.8%
|
-8.13%
|
1.18%
|
-2.48%
|
-7.45%
|
-2.06%
|
Price to Book
|
3.24
x
|
3.38
x
|
5.65
x
|
4.39
x
|
3.1
x
|
8.3
x
|
Nbr of stocks (in thousands)
|
5,016
|
5,016
|
5,016
|
5,603
|
5,603
|
5,937
|
Reference price
2 |
13,800
|
10,100
|
13,800
|
15,350
|
7,410
|
14,700
|
Announcement Date
|
12/31/19
|
2/29/20
|
3/1/21
|
3/1/22
|
3/1/23
|
2/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
4,114
|
6,277
|
8,516
|
10,267
|
8,662
|
5,611
|
EBITDA
1 |
-3,813
|
-2,214
|
1,313
|
2,346
|
-1,381
|
-3,849
|
EBIT
1 |
-5,151
|
-4,260
|
-1,047
|
-321.4
|
-4,325
|
-6,717
|
Operating Margin
|
-125.2%
|
-67.87%
|
-12.29%
|
-3.13%
|
-49.93%
|
-119.71%
|
Earnings before Tax (EBT)
1 |
-8,320
|
-6,645
|
-2,462
|
-1,690
|
-6,205
|
-9,079
|
Net income
1 |
-7,164
|
-6,645
|
-2,462
|
-1,690
|
-6,205
|
-9,079
|
Net margin
|
-174.12%
|
-105.86%
|
-28.91%
|
-16.46%
|
-71.63%
|
-161.82%
|
EPS
2 |
-1,430
|
-1,325
|
-490.8
|
-323.4
|
-1,107
|
-1,595
|
Free Cash Flow
1 |
-9,360
|
-4,456
|
902.4
|
-2,192
|
-3,611
|
-1,929
|
FCF margin
|
-227.5%
|
-70.98%
|
10.6%
|
-21.35%
|
-41.69%
|
-34.39%
|
FCF Conversion (EBITDA)
|
-
|
-
|
68.71%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/31/19
|
2/29/20
|
3/1/21
|
3/1/22
|
3/1/23
|
2/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
4,112
|
7,081
|
2,281
|
6,954
|
6,335
|
Net Cash position
1 |
1,442
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-1.857
x
|
5.392
x
|
0.9726
x
|
-5.035
x
|
-1.646
x
|
Free Cash Flow
1 |
-9,360
|
-4,456
|
902
|
-2,192
|
-3,611
|
-1,929
|
ROE (net income / shareholders' equity)
|
-31.6%
|
-36.5%
|
-18.1%
|
-10.6%
|
-37.6%
|
-75.9%
|
ROA (Net income/ Total Assets)
|
-10.6%
|
-8.05%
|
-2.11%
|
-0.63%
|
-9.27%
|
-17.9%
|
Assets
1 |
67,713
|
82,548
|
116,604
|
267,770
|
66,916
|
50,699
|
Book Value Per Share
2 |
4,265
|
2,989
|
2,441
|
3,499
|
2,391
|
1,772
|
Cash Flow per Share
2 |
296.0
|
153.0
|
218.0
|
221.0
|
85.70
|
171.0
|
Capex
1 |
9,266
|
3,032
|
482
|
838
|
1,552
|
127
|
Capex / Sales
|
225.22%
|
48.31%
|
5.67%
|
8.16%
|
17.92%
|
2.26%
|
Announcement Date
|
12/31/19
|
2/29/20
|
3/1/21
|
3/1/22
|
3/1/23
|
2/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -4.08% | 61.18M | | +56.86% | 823B | | +44.94% | 641B | | -6.57% | 352B | | +17.32% | 324B | | +9.94% | 301B | | +15.47% | 241B | | +1.27% | 223B | | +12.98% | 218B | | +7.98% | 167B |
Other Pharmaceuticals
|